open access

Vol 9, No 3 (2003)
Original papers
Published online: 2003-05-26
Get Citation

Buflomedil associated with pentoxifylline in the treatment of patients with intermittent claudication. Opened, randomised, one-centre-based study

Arkadiusz Jawień, Tomasz Grzela, Marek Ciecierski, Radosław Piotrowicz, Artur Szotkiewicz, Arkadiusz Migdalski
Acta Angiologica 2003;9(3):109-122.

open access

Vol 9, No 3 (2003)
Original papers
Published online: 2003-05-26

Abstract

Background. It has been known that modification of risk factors for atherosclerosis improves the walking distance of patients with intermittent claudication. On the other hand there are variety of different drugs widely used by physicians to meet the patients expectations. We decided to study whether a combine medical therapy has an impact on walking distance among the patients with intermittant claudication.
Material and methods. In a randomised, prospective study, 79 patients with chronic arterial occlusive disease (Fontaine stage II) were treated either by buflomedil (600 mg daily) and pentoxifylline (1200 mg daily) or by pentoksyfilline (1200 mg daily) alone over 12 weeks. All patients underwent treadmill testing at the beginning and at the end of the study (treadmill speed 3,2 km/h and of 12° incline). The pain-free and maximal walking distance were measured at both time points.
Results. The pain-free distance was significantly improved in both groups (74,4% - buflomedil and pentoxifylline group and 27,3% - pentoxifylline group) whereas the total walking distances was significantly higher only in the group of treated by buflomedil and pentoxifylline (41,8%). The percentage of side-effects and adverse events were equal among the studied groups.
Conclusion. The combine treatment of buflomedil with pentoxifylline turned out to be effective and safe for the patients with intermittent claudication.

Abstract

Background. It has been known that modification of risk factors for atherosclerosis improves the walking distance of patients with intermittent claudication. On the other hand there are variety of different drugs widely used by physicians to meet the patients expectations. We decided to study whether a combine medical therapy has an impact on walking distance among the patients with intermittant claudication.
Material and methods. In a randomised, prospective study, 79 patients with chronic arterial occlusive disease (Fontaine stage II) were treated either by buflomedil (600 mg daily) and pentoxifylline (1200 mg daily) or by pentoksyfilline (1200 mg daily) alone over 12 weeks. All patients underwent treadmill testing at the beginning and at the end of the study (treadmill speed 3,2 km/h and of 12° incline). The pain-free and maximal walking distance were measured at both time points.
Results. The pain-free distance was significantly improved in both groups (74,4% - buflomedil and pentoxifylline group and 27,3% - pentoxifylline group) whereas the total walking distances was significantly higher only in the group of treated by buflomedil and pentoxifylline (41,8%). The percentage of side-effects and adverse events were equal among the studied groups.
Conclusion. The combine treatment of buflomedil with pentoxifylline turned out to be effective and safe for the patients with intermittent claudication.
Citation Formats

Keywords

PAOD; intermittent claudication; buflomedil; pentoxifylline

About this article
Title

Buflomedil associated with pentoxifylline in the treatment of patients with intermittent claudication. Opened, randomised, one-centre-based study

Journal

Acta Angiologica

Issue

Vol 9, No 3 (2003)

Pages

109-122

Published online

2003-05-26

Bibliographic record

Acta Angiologica 2003;9(3):109-122.

Keywords

PAOD
intermittent claudication
buflomedil
pentoxifylline

Authors

Arkadiusz Jawień
Tomasz Grzela
Marek Ciecierski
Radosław Piotrowicz
Artur Szotkiewicz
Arkadiusz Migdalski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl